Retinal Vein Occlusion
📧 Sign up to get email alerts when something new happens for Retinal Vein Occlusion.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-21EMA Authorised: Eylea (aflibercept) — Bayer AG
EMA authorises Eylea (aflibercept) for multiple ocular conditions including wet age-related macular degeneration and diabetic eye diseases.
-
EMA approval · 2026-08-18EMA Authorised: Vislyfa (ranibizumab) — Lupin Europe GmbH
The EMA has authorised Vislyfa (ranibizumab) by Lupin Europe GmbH for multiple retinal and diabetic eye diseases, expanding access to this a…
-
EMA approval · 2026-07-03EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
Aflibercept-based therapy Opuviz has been authorised in the EU for multiple ocular conditions including wet age-related macular degeneration…
-
EMA approval · 2026-07-01EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and…
-
EMA approval · 2026-06-16EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) by Celltrion Healthcare Hungary Kft. for multiple retinal diseases including wet age-related macular …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-24EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH
EMA authorised Ranluspec (ranibizumab) from Lupin Europe GmbH. The product is indicated for several retinal conditions including wet age-rel…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab
Clinical trial investigating the effects of intravitreal bevacizumab on serum cholinesterases, paraoxonase, and cardiovascular risk in patie…
-
EMA approval · 2026-04-14EMA Authorised: Pavblu (aflibercept) — Amgen Technology (Ireland) UC
EMA has authorised Pavblu (aflibercept) by Amgen Technology (Ireland) UC for multiple ocular indications including wet age-related macular d…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
A Bayer-sponsored clinical trial project in Germany aims to quantify how many patients suffer from major eye diseases and explores new metho…
-
EMA approval · 2026-04-10EMA Authorised: Mynzepli (aflibercept) — Advanz Pharma Limited
The European Union has authorised Mynzepli (aflibercept) from Advanz Pharma Limited for multiple retinal diseases, including wet age-related…
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases
A completed clinical trial compared the treatment burden of intravitreal anti-VEGF therapy across three retinal diseases: age-related macula…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections [Phase 4]
Phase 4 clinical trial evaluating anesthetic options for intravitreal injections. It compares chloroprocaine HCl ophthalmic gel 3% with prop…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: National Eye Institute Biorepository for Retinal Diseases
This document is a clinical trial update announcing the National Eye Institute Biorepository for Retinal Diseases, which is currently recrui…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy [Phase 2]
A Phase 2 study of SCD411 in adults with wet age-related macular degeneration, retinal vein occlusion, diabetic macular edema, or diabetic r…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety [NA]
A randomized trial evaluating speculum-free intravitreal injection using cotton-tipped applicator retraction, assessing pain, procedure time…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Hoffmann-La Roche reports a real-world, observational study to gain clinical insights into Roche ophthalmology products across several retin…
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and Glaucoma [NA]
This clinical trial update notes enrollment by invitation for a study evaluating AI-assisted detection of posterior segment diseases, includ…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease [NA]
This clinical trial update from Johns Hopkins University describes recruitment for a study evaluating optical coherence tomography angiograp…
-
EMA approval · 2026-03-04EMA Authorised: Eylea (aflibercept) — Bayer AG
The EMA authorised Eylea (aflibercept) from Bayer AG for multiple ocular indications, including wet age-related macular degeneration, macula…
-
EMA approval · 2026-03-03EMA Authorised: Afqlir (aflibercept) — Sandoz GmbH
The EMA authorised Afqlir (aflibercept) from Sandoz GmbH for retinal conditions including wet age-related macular degeneration, macular edem…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment [Phase 4]
A Phase 4 clinical trial is investigating mecobalamin with anti-VEGF intravitreal injections for retinal vein occlusion. The study is curren…
-
EMA approval · 2026-02-26EMA Authorised: Yesafili (aflibercept) — Biosimilar Collaborations Ireland Limited
Yesafili is an authorised aflibercept biosimilar by Biosimilar Collaborations Ireland Limited for various retinal diseases, expanding treatm…
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
This clinical trial update describes a real-world evidence study evaluating the use of faricimab in diabetic macular edema, neovascular age-…
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium [EARLY_Phase 1]
Phase 1 feasibility and safety trial evaluating MB-102 for ocular angiography versus fluorescein sodium is currently recruiting. The study t…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy [Phase 1]
Phase 1 trial update on autologous intravitreal CD34+ stem cells for retinopathy; the study is currently active but not recruiting.